Infliximab in steroid-dependent ulcerative colitis: Effectiveness and predictors of clinical and endoscopic remission

Inflammatory Bowel Diseases

Volumn 19, Issue 4, 2013, Pages 1065-1072

  Armuzzi, Alessandro ^a   Pugliese, Daniela ^a   Danese, Silvio ^b   Rizzo, Gianluca ^c   Felice, Carla ^a   Marzo, Manuela ^a   Andrisani, Gialuca ^a   Fiorino, Gionata ^b   Sociale, Orsola ^b   Papa, Alfredo ^a   Vitis, Italo De ^a   Rapaccini, Gian Lodovico ^a   Guidi, Luisa ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^c CATHOLIC UNIVERSITY   (Italy)

Author keywords

Infliximab; Steroid dependent ulcerative colitis

Indexed keywords

C REACTIVE PROTEIN; INFLIXIMAB; MERCAPTOPURINE; AZATHIOPRINE; CORTICOSTEROID; MESALAZINE; PREDNISOLONE; PREDNISONE; STEROID;

ADULT; ARTICLE; COLON RESECTION; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; REMISSION; RETROSPECTIVE STUDY; TREATMENT RESPONSE; ULCER HEALING; ULCERATIVE COLITIS; CLINICAL ASSESSMENT; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DRUG SAFETY; HAZARD RATIO; HEALING; INTESTINE MUCOSA; MUCOSAL HEALING; PREDICTOR VARIABLE; RISK REDUCTION; STEROID DEPENDENT ULCERATIVE COLITIS; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; C-REACTIVE PROTEIN; COLECTOMY; COLITIS, ULCERATIVE; COMBINED MODALITY THERAPY; ENDOSCOPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; REMISSION INDUCTION; RETROSPECTIVE STUDIES; STEROIDS;

EID: 84876378296     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0b013e3182802909     Document Type: Article

References (31)

1. Faubion WA Jr, Loftus EV Jr, Harmsen WS, et al. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology. 2001;121:255-260.
2. Bianchi Porro G, Cassinotti A, Ferrara E, et al. Review article: the management of steroid dependency in ulcerative colitis. Aliment Pharmacol Ther. 2007;26:779-794.
3. Travis SPL, Stange EF, Lemann L, et al. European evidenced-based consensus on the management of ulcerative colitis: current management. J Crohn's Colitis. 2008;2:24-62.
4. Ardizzone S, Maconi G, Russo A, et al. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut. 2006;55:47-53.
5. Rutgeerts P, Sandborn WJ, Feagan B, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;233:2462-2473.
6. Su C, Salzberg BA, Lewis JD, et al. Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis. Am J Gastroenterol. 2002;97: 2577-2584.
7. Ljung T, Karlén P, Schmidt D, et al. Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County. Gut. 2004;53:849-853.
8. Bermejo F, López-Sanroman A, Hinojosa J, et al. Infliximab induces clinical, endoscopic and histological responses in refractory ulcerative colitis. Rev Esp Enferm Dig. 2004;96:94-101.
9. Kountouras J, Zavos C, Chatzopoulos D. Anti-tumor necrosis factor therapy for ulcerative colitis. Gastroenterology. 2005;129:1138-1139.
10. Gavalas E, Kountouras J, Stergiopoulos C, et al. Efficacy and safety of infliximab in steroid-dependent ulcerative colitis patients. Hepatogastroenterology. 2007;54:1074-1079.
11. Barreiro-de Acosta M, Lorenzo A, Mera J, et al. Mucosal healing and steroid-sparing associated with infliximab for steroid-dependent ulcerative colitis. J Crohns Colitis. 2009;3:271-276.
12. Armuzzi A, De Pascalis B, Lupascu A, et al. Infliximab in the treatment of steroid-dependent ulcerative colitis. Eur Rev Med Pharmacol Sci. 2004;8: 231-233.
13. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005;19(suppl A):5-36.
14. Stange EF, Travis SP, Vermeire S, et al. European evidence-based consensus on the diagnosis and management of ulcerative colitis: definitions and diagnosis. J Crohns Colitis. 2008;2:1-23.
15. Powell-Tuck J, Bown RL, Lennard-Jones JE. A comparison of oral prednisolone given as single or multiple daily doses for active proctocolitis. Scand J Gastroenterol. 1978;13:833-837.
16. Baron JH, Connell AM, Lennard-Jones JE. Variation between observer in describing mucosal appearances in proctocolitis. Br Med J. 1964;1:89-92.
17. Lichtenstein GR, Abreu MT, Cohen R, et al. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology. 2006;130:940-987.
18. Ghosh S, Chaudhary R, Carpani M, et al. Is thiopurine therapy in ulcerative colitis as effective as in Crohn's disease? Gut. 2006;55:6-8.
19. Lopez-Sanroman A, Bermejo F, Carrera E, et al. Efficacy and safety ofthiopurinic immunomodulators (azathioprine and mercaptopurine) in steroiddependent ulcerative colitis. Aliment Pharmacol Ther. 2004;15:161-166.
20. Mantzaris GJ, Sfakianakis M, Archavlis E, et al. A prospective randomized observer-blind 2-year trial of azathioprine monotherapy versus azathioprine and olsalazine for the maintenance of remission of steroiddependent ulcerativie colitis. Am J Gastroenterol. 2004;99:1122-1128.
21. Sood A, Midha V, Sood N, et al. Role of azathioprine in severe ulcerative colitis: one-year, placebo-controlled, randomized trial. Indian J Gastroenterol. 2000;19:14-16.
22. Mate-Jimenez J, Hermida C, Cantero-Perona J, et al. 6-mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid-dependent inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2000;12:1227-1233.
23. Panaccione R, Rutgeerts P, Sandborn WJ, et al. Review article: treatment algorithms to maximize remission and minimize corticosteroid dependence in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2008;28:674-688.
24. Velayos F, Mahadevan U. Management of steroid-dependent ulcerative colitis: immunomodulatory agents, biologics, or surgery? Clin Gastroenterol Hepatol. 2007;5:668-671.
25. Sandborn WJ, Rutgeerts P, Feagan BG, et al. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology. 2009;137:1250-1260.
26. Ferrante M, Vermeire S, Fidder H, et al. Long-term outcome after infliximab for refractory ulcerative colitis. J Crohns Colitis. 2008;2:219-225.
27. Oussalah A, Evesque L, Laharie D, et al. A multicenter experience with infliximab for ulcerative colitis: outcomes and predictors of response, optimization, colectomy and hospitalization. Am J Gastroenterol. 2010; 105:2617-2625.
28. Jürgens M, Mahachie John JM, Cleynen J, et al. Levels of C-reactive protein are associated with response to infliximab therapy in patients with Crohn's disease. Clin Gastroenterol Hepatol. 2011;9:421-427.
29. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010;362: 1383-1395.
30. Panaccione R, Ghosh S, Middleton S, et al. Infliximab, azathioprine, or infliximab + azathioprine for treatment of moderate to severe ulcerative colitis: the UC SUCCESS trial. J Crohns Colitis. 2011;5:S164. Abstract.
31. Lichtenstein GR, Diamond RH, Wagner CL, et al. Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials. Aliment Pharmacol Ther. 2009;30: 210-226.